These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3591710)

  • 1. Preclinical pharmacology of pirmenol.
    Kaplan HR; Mertz TE; Steffe TJ
    Am J Cardiol; 1987 Jun; 59(16):2H-9H. PubMed ID: 3591710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pirmenol: preclinical pharmacology.
    Kaplan HR; Mertz TE; Steffe TJ
    Angiology; 1988 Mar; 39(3 Pt 2):281-92. PubMed ID: 3281517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirmenol hydrochloride (CI-845): antiarrhythmic profile in coronary artery ligated conscious dogs.
    Mertz TE; Steffe TJ
    J Cardiovasc Pharmacol; 1980; 2(5):527-41. PubMed ID: 6157947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiologic and antiarrhythmic actions of pirmenol on rabbit and guinea pig cardiac preparations.
    Sawanobori T; Adaniya H; Yamashita K; Kawano S; Hayami H; Kuga K; Hiraoka M
    J Cardiovasc Pharmacol; 1990 Dec; 16(6):975-83. PubMed ID: 1704993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology and pharmacokinetics of pirmenol.
    Reiter MJ
    Angiology; 1988 Mar; 39(3 Pt 2):293-8. PubMed ID: 3281518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of oral pirmenol.
    Ellenbogen KA; Roark SF; Sintetos AL; Smith MS; McCarthy EA; Smith WM; Kates RE; Pritchett EL
    Clin Pharmacol Ther; 1987 Oct; 42(4):405-10. PubMed ID: 3665339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.
    Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN
    Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical pharmacokinetics of pirmenol.
    Chang T
    Am J Cardiol; 1987 Jun; 59(16):15H-19H. PubMed ID: 2438922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electrophysiologic effects of pirmenol, its metabolite 2, and enantiomers, on cardiac Purkinje fibers.
    Lee JH; Rosen MR
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):416-22. PubMed ID: 7504132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical toxicology of pirmenol hydrochloride.
    Martin RA; de la Iglesia FA
    Am J Cardiol; 1987 Jun; 59(16):10H-14H. PubMed ID: 3591709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pirmenol hydrochloride (CI-845) and reference antiarrhythmic agents: effects on early ventricular arrhythmias after acute coronary artery ligation in anesthetized rats.
    Mertz TE; Kaplan HR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):580-6. PubMed ID: 7131307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy, electrophysiologic and electrocardiographic effects of intravenous pirmenol, a new class I antiarrhythmic agent, in patients with ventricular tachycardia: comparison with procainamide.
    Gold RL; Frumin H; Haffajee CI; Kerin NZ; Jarandilla R
    Pacing Clin Electrophysiol; 1988 Mar; 11(3):308-14. PubMed ID: 2452418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pirmenol HCl on electrophysiologic properties of cardiac Purkinje fibers.
    Reder RF; Danilo P; Rosen MR
    Eur J Pharmacol; 1980 Feb; 61(4):321-33. PubMed ID: 7371711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of pirmenol enantiomers in coronary artery ligated dogs.
    Janiczek N; Smith DE; Chang T; Ventura A; Mertz TE
    J Pharm Sci; 1997 Apr; 86(4):443-9. PubMed ID: 9109046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pirmenol: an antiarrhythmic drug with unique electrocardiographic features--a double-blind placebo-controlled comparison with quinidine.
    Salerno DM; Fifield J; Farmer C; Hodges M
    Clin Cardiol; 1991 Jan; 14(1):25-32. PubMed ID: 2019027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic evaluation of pirmenol for sustained ventricular tachycardia secondary to coronary artery disease.
    Easley AR; Mann DE; Reiter MJ; Sakun V; Sullivan SM; Magro SA; Luck JC; Wyndham CR
    Am J Cardiol; 1986 Jul; 58(1):86-9. PubMed ID: 3728337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic plasma concentrations of pirmenol on canine ventricular arrhythmias.
    Hashimoto K; Watanabe K; Sugiyama A
    Jpn J Pharmacol; 1988 Oct; 48(2):273-82. PubMed ID: 3210450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute electrophysiologic effects of pirmenol in normal subjects and in patients with Wolff-Parkinson-White syndrome.
    Brown JE; Yee R; Klein GJ
    Am J Cardiol; 1986 Apr; 57(10):775-81. PubMed ID: 3962864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiology and antiarrhythmic efficacy of intravenous pirmenol in patients with sustained ventricular tachyarrhythmias.
    Liem LB; Clay DA; Franz MR; Swerdlow CD
    Am Heart J; 1987 Jun; 113(6):1390-6. PubMed ID: 3591608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute haemodynamic effects of the antiarrhythmic agent pirmenol in cardiac patients: a comparison with lidocaine.
    Nieminen MS; Toivonen LK; Manninen V; Frick MH
    Eur Heart J; 1986 Feb; 7(2):150-7. PubMed ID: 3516703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.